Pangaea Data has entered into a multi-year collaboration agreement with Alexion, AstraZeneca’s subsidiary focused on rare diseases, to co-develop, clinically validate, and seek regulatory approval for an AI-enabled clinical decision support system targeting the detection of hypophosphatasia (HPP) in adults. The strategic AI partnership, formalized in March 2025, leverages Pangaea’s existing platform to address diagnostic delays in this challenging, rare bone disorder.
Hypophosphatasia affects bone mineralization and tooth development, with mild forms impacting one in 6,000 to 7,000 people, while severe variants affect one in 100,000 to 300,000 newborns annually. The collaboration addresses a critical unmet need, as rare disease diagnosis typically requires significantly longer timeframes than common conditions due to clinical complexity and physician unfamiliarity.
The partnership centers on developing an Artificial Intelligence Clinical Data Support System (AI-CDSS) that seamlessly integrates into existing electronic health record workflows. Pangaea’s platform analyzes dental records, family history, and alkaline phosphatase lab results within 8-10 minutes, operating invisibly within physician workflows without requiring additional applications or workflow disruptions.
“As a clinician, you have 15,000 or 20,000 hard-to-diagnose conditions, and there’s a very high chance you would think about the things that you heard about,” explained Vibhor Gupta, Pangaea Data’s founder and CEO. The AI partnership aims to eliminate these diagnostic blind spots through automated pattern recognition across multiple health systems spanning nine countries.
Pangaea’s AI platform currently identifies 42 care gaps across 16 hard-to-diagnose conditions, including chronic obstructive pulmonary disease (COPD) and ovarian cancer. The Alexion collaboration represents a strategic expansion into metabolic bone disorders, positioning both companies to capture market share in precision diagnostics for rare diseases.
The strategic AI partnership reflects broader industry trends toward AI-enabled rare disease identification, with particular focus on conditions where delayed diagnosis significantly impacts patient outcomes. Financial terms remain undisclosed, though the multi-year structure suggests substantial milestone-based commitments aligned with regulatory validation timelines.
Industry analysts anticipate the collaboration could accelerate FDA breakthrough device designation pathways, particularly given Alexion’s established rare disease commercialization expertise and Pangaea’s proven AI diagnostic capabilities across multiple therapeutic areas.
